{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:06:59Z","timestamp":1792480019598,"version":"4.5.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The toxicities associated with immune checkpoint inhibitors (ICIs) can affect nearly all organ systems. Although previous studies have examined specific types of immune-related adverse events (irAEs) associated with ICIs, comprehensive evaluations of the clinical profiles of irAEs using data from the FDA Adverse Event Reporting System database over an extended period have been lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Duplicate records and reports submitted by nonprofessionals were removed for data cleaning. Employing three disproportional statistical methods (Reporting Odds Ratio, Bayesian Confidence Propagation Neural Network, and Multi-Item Gamma Poisson Shrinker) with MedDRA version 27.1 classification, we identified and ranked adverse event signals across System Organ Class (SOC), Standardized MedDRA Query (SMQ), and Preferred Term (PT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 320,556 adverse event reports associated with eight ICIs, involving 123,210 patients, were included in the analysis. At the SOC level, endocrine disorders and hepatobiliary disorders exhibited the strongest signals, while cardiac and respiratory toxicities showed the highest mortality risks across vital organ systems. At the SMQ level, the most prominent signals included noninfectious encephalitis, hypothyroidism, noninfectious myocarditis\/pericarditis, eosinophilic pneumonia, and interstitial lung disease. At the PT level, the leading signals were immune-mediated lung disease, immune-mediated enterocolitis, immune-mediated hepatitis, (immune-mediated) myocarditis, hypophysitis, and adrenal insufficiency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This pharmacovigilance study provides a systematic analysis of the clinical spectrum and reporting characteristics of ICI-related irAEs, comparing relative risks across vital organ systems and laying the foundation for interdisciplinary collaboration among oncologists and relevant specialists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1823743","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:25Z","timestamp":1777613725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive safety analysis of the clinical spectrum of adverse events associated with immune checkpoint inhibitors based on FAERS"],"prefix":"10.3389","volume":"17","author":[{"given":"Caihong","family":"Qu","sequence":"first","affiliation":[{"name":"Office of Pharmacovigilance, Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Wang","sequence":"additional","affiliation":[{"name":"Information Center, Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-024-03858-4","article-title":"Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database","volume":"74","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002607","article-title":"Immunotherapy-induced cholestasis in cancer: insights from the two real-world pharmacovigilance databases of FAERS and VigiBase","volume":"111","author":"Yan","year":"2025","journal-title":"Int J Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0325760","article-title":"Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database","volume":"20","author":"Frey","year":"2025","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1186\/s12885-025-14668-x","article-title":"Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database","volume":"25","author":"Yao","year":"2025","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-090087","article-title":"Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database","volume":"15","author":"Shan","year":"2025","journal-title":"BMJ Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2443961","article-title":"Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases","author":"Utsunomiya","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7659","DOI":"10.1038\/s41598-024-58460-6","article-title":"Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.892503","article-title":"Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions","volume":"13","author":"Guan","year":"2022","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0216","article-title":"Full spectrum: efficacy and toxicity of immunotherapy in metastatic melanoma","volume":"12","author":"Zibelman","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.013","article-title":"Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies","volume":"129","author":"Baldini","year":"2020","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1804","article-title":"Endocrine adverse events caused by different types and different doses of immune checkpoint inhibitors in the treatment of solid tumors: A meta-analysis and systematic review","volume":"61","author":"Yang","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009742","article-title":"Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events","volume":"12","author":"Shatila","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.09.042","article-title":"Autoimmune pancreatitis secondary to immune checkpoint inhibitor therapy (Type 3 AIP): insights into a new disease from serial pancreatic imaging","volume":"164","author":"Thomas","year":"2023","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: Management of Immunotherapy-Related Toxicities, version 2.2024: Featured updates to the NCCN guidelines","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002332","article-title":"IL12\/23 blockade for refractory immune-mediated colitis: 2-center experience","volume":"118","author":"Shirwaikar Thomas","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-075859","article-title":"Cardiovascular toxicity of immune therapies for cancer","volume":"385","author":"Palaskas","year":"2024","journal-title":"BMJ"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor-related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01257-6","article-title":"Management of pulmonary toxicities associated with systemic therapy in non small cell lung cancer","volume":"25","author":"Velimirovic","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13915","article-title":"Pulmonary toxicity of systemic lung cancer therapy","author":"Long","year":"2020","journal-title":"Respirology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.021","article-title":"Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC","volume":"15","author":"Dumoulin","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701951","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.08.044","article-title":"Ophthalmic immune-related adverse events and association with survival: results from a real-world database","volume":"268","author":"Quiruz","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41584-020-00546-2","article-title":"Spectrum and impact of checkpoint inhibitor-induced irAEs","volume":"17","author":"Cappelli","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-01019-7","article-title":"Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management","volume":"22","author":"Triantafyllou","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2019","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0523-2","article-title":"A case report of clonal EBV-like memory CD4(+) T cell activation in fatal checkpoint inhibitor-induced encephalitis","volume":"25","author":"Johnson","year":"2019","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.10.006","article-title":"Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity","volume":"141","author":"Mazzarella","year":"2020","journal-title":"Eur J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011404","article-title":"IL-1\u03b2 blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity","volume":"13","author":"Talele","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1553882","article-title":"Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase ib clinical trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823743\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:26Z","timestamp":1777613726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1823743\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1823743"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1823743","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1823743"}}